Ignite Creation Date:
2025-12-25 @ 3:27 AM
Ignite Modification Date:
2026-01-16 @ 8:02 PM
Study NCT ID:
NCT02200705
Status:
COMPLETED
Last Update Posted:
2025-04-30
First Post:
2014-07-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ronitl@icecure-medical.com', 'phone': '+972-4-623-0333', 'title': 'Clinical Trial Manager', 'organization': 'IceCure Medical'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'Adverse events were collected through 2 years post-procedure, and serious adverse events (SAEs) were collected through the final follow-up (5 years post-procedure).', 'eventGroups': [{'id': 'EG000', 'title': 'Single Arm, Open Label', 'description': 'Subjects with early-stage (up to 1.5 cm), low-risk breast cancer who met the eligibility criteria outlined in the study protocol were enrolled and underwent cryoablation using the IceCure Medical Ice-Sense3™/ProSense™ system.', 'otherNumAtRisk': 206, 'deathsNumAtRisk': 206, 'otherNumAffected': 97, 'seriousNumAtRisk': 206, 'deathsNumAffected': 21, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Pain', 'notes': '39 events of local pain. 1 non-cardiac chest pain and 1 pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 206, 'numEvents': 41, 'numAffected': 39}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE v.4.03'}, {'term': 'Localized Edema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 206, 'numEvents': 40, 'numAffected': 39}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE v.4.03'}, {'term': 'Bruising', 'stats': [{'groupId': 'EG000', 'numAtRisk': 206, 'numEvents': 62, 'numAffected': 61}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE v.4.03'}, {'term': 'Frost Injury', 'notes': 'Skin burn', 'stats': [{'groupId': 'EG000', 'numAtRisk': 206, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE v.4.03'}, {'term': 'Hematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 206, 'numEvents': 9, 'numAffected': 9}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE v.4.03'}, {'term': 'Rash & Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 206, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE v.4.03'}, {'term': 'Injection site reaction', 'notes': 'Including tenderness and skin reactions', 'stats': [{'groupId': 'EG000', 'numAtRisk': 206, 'numEvents': 11, 'numAffected': 10}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE v.4.03'}], 'frequencyThreshold': '2'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Local Inbreast Breast Tumor Recurrence (IBTR) Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '194', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Single Arm, Open Label', 'description': 'Subjects with early-stage (up to 1.5 cm), low-risk breast cancer who met the eligibility criteria outlined in the study protocol were enrolled and underwent cryoablation using the IceCure Medical Ice-Sense3™/ProSense™ system.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.3', 'groupId': 'OG000', 'lowerLimit': '2.1', 'upperLimit': '8.7'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'up to 5 years', 'description': '6 months post cryoabltion, then annually for 5 years', 'unitOfMeasure': 'Percentage of participants with IBTR', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Complete Ablation of Primary Tumor', 'timeFrame': 'up to 5 years from procedure date.', 'description': 'Complete ablation of primary tumor up to 60 months after cryoablation', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': "Improvement or Maintenance of Subject's Quality of Life", 'timeFrame': 'at 6 months compare to the base line', 'description': 'Quality of life will be assesed using NCCN DISTRESS THERMOMETER', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Breast Cosmetics Satisfaction', 'timeFrame': 'up to 5 years from procedure data.', 'description': 'subjects and physician satisfaction from the cosmetic results', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Regional Recurrence Rate', 'timeFrame': 'up to 5 years', 'description': 'Regional Invasive breast tumor recurrence rate.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Distant Metastases Rate', 'timeFrame': 'up to 5 years', 'description': 'Distant metastases rate including contralateral Breast cancer', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Disease-free Survival (DFS)', 'timeFrame': 'up to 5 years', 'description': 'DFS from date of complete ablation of the primary tumor, until the first disease event where the disease event is defined as local (DCIS or invasive), regional, or distant breast cancer recurrence, second primary cancer, DCIS or invasive contralateral breast cancer, or death due to any cause', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Overall Survival', 'timeFrame': 'up to 5 years', 'description': 'Overall survival from the date of the cryoablation until the date of death from any cause or up to the 60 months follow up visit', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Breast Cancer Survival.', 'timeFrame': 'up to 5 years', 'description': 'Breast Cancer Survival from the date of cryoablation until the date of death from breast cancer or up to the 60 months follow-up visit.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Adverse Events', 'timeFrame': 'up to 2 years for AEs and up to 5 years for SAEs', 'description': 'Adverse events related to study device or procedure rate', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Single Arm, Open Label', 'description': 'Subjects with early-stage (up to 1.5 cm), low-risk breast cancer who met the eligibility criteria outlined in the study protocol were enrolled and underwent cryoablation using the IceCure Medical Ice-Sense3™/ProSense™ system.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '206'}]}, {'type': 'Per-protocol Study Population', 'achievements': [{'groupId': 'FG000', 'numSubjects': '194'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '131'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '75'}]}], 'dropWithdraws': [{'type': 'Excluded', 'reasons': [{'groupId': 'FG000', 'numSubjects': '12'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '21'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '22'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '13'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}]}]}], 'recruitmentDetails': 'The study was conducted at 19 sites in the USA. All study investigators had related experience in low-risk breast cancer treatment, imaging, and pathology assessments and were trained to perform the cryoablation procedure. The recruitment period lasted from October 2014 to February 2019.', 'preAssignmentDetails': 'A total of 212 Subjects were screened for enrollment in the study; 3 were screen failures, and 3 subjects withdrew consent before the procedure; 206 were enrolled and treated. Based on the DSMB recommendation, 12 subjects were excluded from the study after completing the cryoablation procedure. Nine (9) were due to deviation from inclusion criteria, and three (3) were due to incomplete treatment, resulting in the per-protocol study population of 194 subjects.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '194', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Single Arm, Open Label', 'description': 'Subjects with early-stage (up to 1.5 cm), low-risk breast cancer who met the eligibility criteria outlined in the study protocol were enrolled and underwent cryoablation using the IceCure Medical Ice-Sense3™/ProSense™ system.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '74.9', 'spread': '6.9', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '194', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'Ethnicity', 'categories': [{'title': 'African American', 'measurements': [{'value': '14', 'groupId': 'BG000'}]}, {'title': 'Asian', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'Caucasian', 'measurements': [{'value': '160', 'groupId': 'BG000'}]}, {'title': 'Hispanic', 'measurements': [{'value': '12', 'groupId': 'BG000'}]}, {'title': 'Native American', 'measurements': [{'value': '2', 'groupId': 'BG000'}]}, {'title': 'Unknow', 'measurements': [{'value': '5', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '194', 'groupId': 'BG000'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Type of Tumor', 'classes': [{'categories': [{'title': 'Lumina A', 'measurements': [{'value': '188', 'groupId': 'BG000'}]}, {'title': 'Lumina B', 'measurements': [{'value': '3', 'groupId': 'BG000'}]}, {'title': 'Not specified', 'measurements': [{'value': '3', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': "Subtype of breast cancer based on the cancer's molecular characteristics", 'unitOfMeasure': 'Participants'}, {'title': 'ER (Estrogen Receptor)', 'classes': [{'categories': [{'title': 'Positive', 'measurements': [{'value': '194', 'groupId': 'BG000'}]}, {'title': 'Negative', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'Lab assessment (IHC) of the percentage of estrogen receptors on breast cancer cells. ER-positive is defined when ≥1% of tumor cell nuclei stain positive.', 'unitOfMeasure': 'Participants'}, {'title': 'PR (Progesterone Receptor)', 'classes': [{'categories': [{'title': 'Positive', 'measurements': [{'value': '180', 'groupId': 'BG000'}]}, {'title': 'Negative', 'measurements': [{'value': '14', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'Lab assessment (IHC) of the percentage of progesterone receptors on breast cancer cells. PR-positive is defined when ≥1% of tumor cell nuclei stain positive.', 'unitOfMeasure': 'Participants'}, {'title': 'Her2neu', 'classes': [{'categories': [{'title': 'Positive', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Negative', 'measurements': [{'value': '194', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'HER2 status is assessed by IHC to measure the amount of HER2 protein on the surface of breast cancer cells. HER2-negative is no staining or incomplete staining in \\>10% of cells. HER2-positive is strong complete staining in \\>10% of cells. HER2-negative breast cancer is a less aggressive form of cancer than HER2-positive cancers.', 'unitOfMeasure': 'Participants'}, {'title': 'Nottingham Grade (1-3)', 'classes': [{'categories': [{'title': 'Grade 1 (Low grade) - Least aggressive with good prognosis', 'measurements': [{'value': '96', 'groupId': 'BG000'}]}, {'title': 'Grade 2 (Intermediate-grade tumor) - Moderate aggressiveness and prognosis', 'measurements': [{'value': '98', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'The primary analysis set includes 194 subjects (following the DSMB exclusion of 12 subjects).'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2021-10-27', 'size': 229217, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2025-03-17T09:55', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 206}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2014-10', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-04', 'completionDateStruct': {'date': '2024-05-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-04-27', 'studyFirstSubmitDate': '2014-07-22', 'resultsFirstSubmitDate': '2025-03-17', 'studyFirstSubmitQcDate': '2014-07-24', 'lastUpdatePostDateStruct': {'date': '2025-04-30', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2025-04-27', 'studyFirstPostDateStruct': {'date': '2014-07-25', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2025-04-30', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-03-17', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Local Inbreast Breast Tumor Recurrence (IBTR) Rate', 'timeFrame': 'up to 5 years', 'description': '6 months post cryoabltion, then annually for 5 years'}], 'secondaryOutcomes': [{'measure': 'Complete Ablation of Primary Tumor', 'timeFrame': 'up to 5 years from procedure date.', 'description': 'Complete ablation of primary tumor up to 60 months after cryoablation'}, {'measure': "Improvement or Maintenance of Subject's Quality of Life", 'timeFrame': 'at 6 months compare to the base line', 'description': 'Quality of life will be assesed using NCCN DISTRESS THERMOMETER'}, {'measure': 'Breast Cosmetics Satisfaction', 'timeFrame': 'up to 5 years from procedure data.', 'description': 'subjects and physician satisfaction from the cosmetic results'}, {'measure': 'Regional Recurrence Rate', 'timeFrame': 'up to 5 years', 'description': 'Regional Invasive breast tumor recurrence rate.'}, {'measure': 'Distant Metastases Rate', 'timeFrame': 'up to 5 years', 'description': 'Distant metastases rate including contralateral Breast cancer'}, {'measure': 'Disease-free Survival (DFS)', 'timeFrame': 'up to 5 years', 'description': 'DFS from date of complete ablation of the primary tumor, until the first disease event where the disease event is defined as local (DCIS or invasive), regional, or distant breast cancer recurrence, second primary cancer, DCIS or invasive contralateral breast cancer, or death due to any cause'}, {'measure': 'Overall Survival', 'timeFrame': 'up to 5 years', 'description': 'Overall survival from the date of the cryoablation until the date of death from any cause or up to the 60 months follow up visit'}, {'measure': 'Breast Cancer Survival.', 'timeFrame': 'up to 5 years', 'description': 'Breast Cancer Survival from the date of cryoablation until the date of death from breast cancer or up to the 60 months follow-up visit.'}, {'measure': 'Adverse Events', 'timeFrame': 'up to 2 years for AEs and up to 5 years for SAEs', 'description': 'Adverse events related to study device or procedure rate'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'keywords': ['cryoablation, cryotherapy, breast cancer'], 'conditions': ['Breast Cancer']}, 'referencesModule': {'references': [{'pmid': '39909175', 'type': 'DERIVED', 'citation': 'Jean J, Jochelson MS, Moo TA, Solomon SB, Bryce Y. Breast Cancer Recurrence after Cryoablation in Patients Who Are Poor Surgical Candidates or Who Refuse Surgery. J Vasc Interv Radiol. 2025 Jun;36(6):971-978. doi: 10.1016/j.jvir.2025.01.048. Epub 2025 Feb 3.'}]}, 'descriptionModule': {'briefSummary': 'To evaluate the efficacy of cryoablation without lumpectomy and its impact on local and distant recurrence of early stage breast cancer .'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '50 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Competent to sign informed consent\n2. Diagnosis of invasive ductal breast carcinoma by core needle biopsy, meeting the following criteria:\n\n 1. Unifocal primary disease NOTE: Patients with multifocal and/or multicentric in breast cancer, or evidence of EIC are NOT eligible. Patients with contralateral disease will remain eligible.\n 2. Tumor size ≤1.5 cm in greatest diameter in the axis parallel to the treatment probe AND ≤1.5 cm in the axis anti-parallel to the treatment probe AND ≤1.5 cm in Anterior/ Posterior dimension. Tumor size ≤1.5 cm in greatest diameter as measured by breast ultrasound, mammogram and/or MRI. The largest dimension measured will be used to determine eligibility.\n 3. Nottingham grade 1-2. Specifically, nuclear and mitotic scores must be less than or equal to 2.\n 4. Estrogen receptor-positive, progesterone receptor-positive, HER2 negative\n3. Age\\>= 50\n4. Breast size adequate for safe cryoablation\n5. Lesion must be sonographically visible at the time of treatment.\n6. History of previously treated ipsilateral or contralateral breast carcinoma is not an exclusion criteria if the investigator is certain newly diagnosed carcinoma is new unifocal primary tumor.\n\nExclusion Criteria:\n\n1. Presence of lobular carcinoma\n2. Presence of luminal B pathology\n3. Nottingham score of 3 (specially nuclear and mitotic score\\>2)\n4. Presence of microinvasion, or invasive breast carcinoma with extensive intraductal component (EIC)\n5. Presence of multifocal and/or multicentric in breast cancer\n6. Presence of multifocal calcifications\n7. Presence of prior or concurrent neoadjuvant chemotherapy for breast cancer\n8. Presence of prior en bloc open surgical biopsy and/or lumpectomy for diagnosis/treatment of the index breast cancer\n9. Patient that is not suitable to cryoablation procedure according to the physician opinion\n10. ER AND PR negative, or Her2 positive noted on pre-cryo biopsy'}, 'identificationModule': {'nctId': 'NCT02200705', 'briefTitle': 'Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial', 'organization': {'class': 'INDUSTRY', 'fullName': 'IceCure Medical Ltd.'}, 'officialTitle': 'Cryoablation of Low Risk Breast Cancer Less Than 1.5 cm: An Evaluation of Local Recurrence (Ice3 Trial)', 'orgStudyIdInfo': {'id': 'ICMBC-02'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'OTHER', 'label': 'single arm, open label', 'description': 'Early stage Breast cancers up to 1.5cm', 'interventionNames': ['Device: Ice-Sense3TM/ ProSenseTM']}], 'interventions': [{'name': 'Ice-Sense3TM/ ProSenseTM', 'type': 'DEVICE', 'armGroupLabels': ['single arm, open label']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85306', 'city': 'Glendale', 'state': 'Arizona', 'country': 'United States', 'facility': 'Ironwood Cancer & Research Centers', 'geoPoint': {'lat': 33.53865, 'lon': -112.18599}}, {'zip': '92705', 'city': 'Santa Ana', 'state': 'California', 'country': 'United States', 'facility': 'BreastLink', 'geoPoint': {'lat': 33.74557, 'lon': -117.86783}}, {'zip': '06611', 'city': 'Trumbull', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Bridgeport Hospital, Yale Medical School', 'geoPoint': {'lat': 41.24287, 'lon': -73.20067}}, {'zip': '30720', 'city': 'Dalton', 'state': 'Georgia', 'country': 'United States', 'facility': 'Dalton Surgical Group', 'geoPoint': {'lat': 34.7698, 'lon': -84.97022}}, {'zip': '46202-5116', 'city': 'Indianapolis', 'state': 'Indiana', 'country': 'United States', 'facility': 'Indiana University', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '48201', 'city': 'Detroit', 'state': 'Michigan', 'country': 'United States', 'facility': 'Karmanos Cancer Institute', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '48507', 'city': 'Flint', 'state': 'Michigan', 'country': 'United States', 'facility': 'Regional Medical Imaging', 'geoPoint': {'lat': 43.01253, 'lon': -83.68746}}, {'zip': '48085', 'city': 'Troy', 'state': 'Michigan', 'country': 'United States', 'facility': 'Comprehensive Breast Care', 'geoPoint': {'lat': 42.60559, 'lon': -83.14993}}, {'zip': '07728', 'city': 'Freehold', 'state': 'New Jersey', 'country': 'United States', 'facility': 'CentraState Medical Center', 'geoPoint': {'lat': 40.26011, 'lon': -74.27376}}, {'zip': '87114', 'city': 'Albuquerque', 'state': 'New Mexico', 'country': 'United States', 'facility': 'Breast Specialty care/ Presbyterian Hospital', 'geoPoint': {'lat': 35.08449, 'lon': -106.65114}}, {'zip': '10011', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Mount Sinai Beth Israel', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10032', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Columbia University/ NY Presbyterian hospital', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Weill Cornell Medical College', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10467', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Montefiore Medical Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '45227', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'Cincinnati Breast Surgeons Inc.', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '44106', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'facility': 'University hospitals cleveland medical center', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '19107', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Thomas Jefferson University hospital', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '38138', 'city': 'Germantown', 'state': 'Tennessee', 'country': 'United States', 'facility': 'West Clinic', 'geoPoint': {'lat': 35.08676, 'lon': -89.81009}}, {'zip': '75075', 'city': 'Plano', 'state': 'Texas', 'country': 'United States', 'facility': 'Complete Breast Care', 'geoPoint': {'lat': 33.01984, 'lon': -96.69889}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'IceCure Medical Ltd.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}